Bulbospinal muscular atrophy congenital – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bulbospinal muscular atrophy congenital – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Clenbuterol vs Placebo in Adult Patients with Spinal and Bulbar Muscular Atrophy (SBMA) https://clinicaltrials.eu/trial/study-on-clenbuterol-for-treating-spinal-and-bulbar-muscular-atrophy-in-patients/ Wed, 29 Apr 2026 14:59:31 +0000 https://clinicaltrials.eu/trial/study-on-clenbuterol-for-treating-spinal-and-bulbar-muscular-atrophy-in-patients/ This study focuses on Spinal and Bulbar Muscular Atrophy (SBMA), a rare genetic condition that causes muscle weakness and wasting, particularly affecting the muscles used for speaking, swallowing, and limb movement. The study will test a medication called clenbuterol, comparing it with a placebo to determine if it can help people with this condition.

The main purpose is to evaluate how well clenbuterol works and how safe it is when used as a long-term treatment for patients with SBMA. During the study, participants will receive either clenbuterol tablets or placebo tablets for a period of 48 weeks. The medication will be taken by oral route, with a maximum daily dose of 40 micrograms.

Throughout the study, various measurements will be taken to assess how participants respond to the treatment, including their ability to walk and perform daily activities. The study will also monitor breathing function and overall quality of life. Regular check-ups will be conducted to ensure participant safety and to track any changes in their condition.

]]> Study of NIDO-361 for Patients with Spinal and Bulbar Muscular Atrophy (SBMA) https://clinicaltrials.eu/trial/study-of-nido-361-for-patients-with-spinal-and-bulbar-muscular-atrophy-sbma/ Wed, 29 Apr 2026 14:57:22 +0000 https://clinicaltrials.eu/trial/study-of-nido-361-for-patients-with-spinal-and-bulbar-muscular-atrophy-sbma/ This clinical trial is focused on studying a condition known as Spinal and Bulbar Muscular Atrophy (SBMA). SBMA is a rare genetic disorder that affects muscle strength and movement. The trial will test a new treatment called NIDO-361, which is taken as a tablet. The purpose of the study is to see if NIDO-361 can help restore muscle volume and to check its safety when taken once a day by mouth.

Participants in the study will be randomly assigned to receive either the NIDO-361 tablets or placebo tablets. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The trial will last for a period of up to 12 months, during which participants will have regular check-ups to monitor their health and any changes in their muscle condition.

The main focus of the study is to observe changes in muscle volume using MRI scans, which are special imaging tests that provide detailed pictures of the muscles. The study will also track any side effects experienced by participants and assess their overall physical activity and muscle strength through various tests. This research aims to provide valuable information on the potential benefits and safety of NIDO-361 for individuals with SBMA.

]]> KD-UK https://clinicaltrials.eu/organisation/kd-uk/ Wed, 29 Apr 2026 13:34:16 +0000 https://clinicaltrials.eu/organisation/kd-uk/ Kennedy’s Disease UK (KD-UK) is a unique UK-based charity singularly focused on Kennedy’s Disease (KD). Operating as a non-profit organization, it is entirely run by volunteers, many of whom are living with the disease themselves. They are dedicated to helping individuals and families affected by KD to access critical and reliable information about the condition.

]]>